Moomoo AI 已提取核心訊息
Redhill Biopharma Ltd., a foreign private issuer, has submitted a Form 6-K to the United States Securities and Exchange Commission (SEC) for January 2024. The report includes several exhibits such as Securities Purchase Agreement, Warrant forms, and legal opinions from Goldfarb Gross Seligman & Co. and Haynes and Boone, LLP. The Form 6-K filing, which is not an offer to sell or a solicitation of an offer to buy securities, has been incorporated by reference into the company's various Registration Statements on Form S-8 and Form F-3 filed with the SEC over the years. The document was signed by CEO Dror Ben-Asher, indicating compliance with the requirements of the Securities Exchange Act of 1934.
Redhill Biopharma Ltd., a foreign private issuer, has submitted a Form 6-K to the United States Securities and Exchange Commission (SEC) for January 2024. The report includes several exhibits such as Securities Purchase Agreement, Warrant forms, and legal opinions from Goldfarb Gross Seligman & Co. and Haynes and Boone, LLP. The Form 6-K filing, which is not an offer to sell or a solicitation of an offer to buy securities, has been incorporated by reference into the company's various Registration Statements on Form S-8 and Form F-3 filed with the SEC over the years. The document was signed by CEO Dror Ben-Asher, indicating compliance with the requirements of the Securities Exchange Act of 1934.
外國私人發行人紅山生物製藥有限公司已向美國證券交易委員會（SEC）提交了2024年1月的6-K表格。該報告包括一些證物，例如證券購買協議、認股權證表格以及來自Goldfarb Gross Seligman & Co. 和Haynes and Boone, LLP的法律意見書。6K表格申請不是出售要約或徵集購買證券要約，已通過引用方式納入公司多年來向美國證券交易委員會提交的關於S-8表格和F-3表格的各種註冊聲明。該文件由首席執行官德羅爾·本·阿舍爾簽署，表明遵守了1934年《證券交易法》的要求。
外國私人發行人紅山生物製藥有限公司已向美國證券交易委員會（SEC）提交了2024年1月的6-K表格。該報告包括一些證物，例如證券購買協議、認股權證表格以及來自Goldfarb Gross Seligman & Co. 和Haynes and Boone, LLP的法律意見書。6K表格申請不是出售要約或徵集購買證券要約，已通過引用方式納入公司多年來向美國證券交易委員會提交的關於S-8表格和F-3表格的各種註冊聲明。該文件由首席執行官德羅爾·本·阿舍爾簽署，表明遵守了1934年《證券交易法》的要求。
有用
沒用